durvalumab
astrazeneca
['pacific']
#asco22 pleased to present the egfr-mt subgrp analysis of pacific in which we see no diffs in pfs/os with durva v pbo, &amp;no concerning safety signals you know you ve made it when comes to your poster 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University